Alpine Woods Capital Investors, LLC Acadia Pharmaceuticals Inc Transaction History

Alpine Woods Capital Investors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 03, 2022	SELL	$16.79 - $27.09 $638,020 - $1.03 Million	-38,000 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$15.78 - $24.77 $15,780 - $24,770	-1,000 Reduced 2.56%	38,000 $631,000
Q3 2019 Nov 01, 2019	SELL	$22.22 - $44.01 $222,200 - $440,100	-10,000 Reduced 20.41%	39,000 $1.4 Million
Q2 2019 Aug 05, 2019	SELL	$23.32 - $28.12 $186,560 - $224,960	-8,000 Reduced 14.04%	49,000 $1.31 Million
Q1 2019 May 06, 2019	SELL	$16.17 - $27.38 $161 - $273	-10 Reduced 0.02%	57,000 $1.53 Million
Q3 2018 Nov 08, 2018	BUY	$13.03 - $21.81 $338,780 - $567,060	26,000 Added 83.84%	57,010 $1.18 Million
Q2 2018 Aug 09, 2018	BUY	$15.07 - $22.34 $75,500 - $111,923	5,010 Added 19.27%	31,010 $474,000
Q1 2018 May 09, 2018	BUY	$22.47 - $32.33 $112,350 - $161,650	5,000 Added 23.81%	26,000 $584,000
Q4 2017 Feb 14, 2018	BUY	$26.84 - $39.14 $268,400 - $391,400	10,000 Added 90.91%	21,000 $632,000
Q3 2017 Nov 08, 2017	BUY	$29.49 - $38.37 $324,390 - $422,070	11,000	11,000 $414,000

280

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.65B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Alpine Woods Capital Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Alpine Woods Capital Investors, LLC with notifications on news.